Hostname: page-component-848d4c4894-m9kch Total loading time: 0 Render date: 2024-05-14T21:41:47.636Z Has data issue: false hasContentIssue false
  • English
  • Français

Pyrogenic Reactions Associated With Single Daily Dosing of Intravenous Gentamicin

Published online by Cambridge University Press:  02 January 2015

Udo Buchholz ,
Chesley Richards ,
Rekha Murthy ,
Matthew Arduino ,
Doreen Pon ,
Wayne Schwartz ,
Elsie Fontanilla ,
Clare Pegues ,
Noemy Boghossian  and
Carol Peterson
...Show all authors
Udo Buchholz
Affiliation:
Epidemic Intelligence Service, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, Georgia Acute Communicable Disease Control, Los Angeles County Department of Health Services, Los Angeles, California
Chesley Richards*
Affiliation:
Epidemic Intelligence Service, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, Georgia Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, Georgia
Rekha Murthy
Affiliation:
Cedars-Sinai Medical Center, Los Angeles, California
Matthew Arduino
Affiliation:
Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, Georgia
Doreen Pon
Affiliation:
Cedars-Sinai Medical Center, Los Angeles, California
Wayne Schwartz
Affiliation:
Cedars-Sinai Medical Center, Los Angeles, California
Elsie Fontanilla
Affiliation:
Cedars-Sinai Medical Center, Los Angeles, California
Clare Pegues
Affiliation:
Cedars-Sinai Medical Center, Los Angeles, California
Noemy Boghossian
Affiliation:
Cedars-Sinai Medical Center, Los Angeles, California
Carol Peterson
Affiliation:
Acute Communicable Disease Control, Los Angeles County Department of Health Services, Los Angeles, California
Jacob Kool
Affiliation:
Acute Communicable Disease Control, Los Angeles County Department of Health Services, Los Angeles, California
Laurene Mascola
Affiliation:
Acute Communicable Disease Control, Los Angeles County Department of Health Services, Los Angeles, California
William R. Jarvis
Affiliation:
Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, Georgia
*
Centers for Disease Control and Prevention, Hospital Infections Program, Mailstop A-07, 1600 Clifton Rd, Atlanta, GA 30333
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To identify risk factors associated with an unexpected outbreak of pyrogenic reactions (PR) following intravenous gentamicin.

Design:

We conducted two cohort studies. PRs were defined as chills, rigors, or shaking within 3 hours after initiating the gentamicin infusion during the preepidemic (December 1, 1997-January 15,1998) or epidemic (May 1-June 15,1998) periods. We tested gentamicin vials for endotoxin using the limulus amebocyte lysate assay.

Setting:

Inpatient services of a large community hospital in Los Angeles, California.

Results:

During the epidemic period, 22 (15%) of 152 patients developed documented PRs following intravenous gentamicin. PRs were more likely among patients receiving single daily dosing (SDD) than multiple daily dosing gentamicin (20/73 [27%] vs 2/79 [3%]; relative risk, 10.8; 95% confidence interval, 2.644.7). Laboratory analysis of gentamicin vials found endotoxin levels that were higher among Fujisawa-brand gentamicin (implicated brand) than gentamicin used after the outbreak terminated (non-implicated brand). Although endotoxin levels in the vials did not exceed US Pharmacopeia limits (1.7 endotoxin units/mg gentamicin), the use of SDD gentamicin may place patients at greater risk of receiving doses of endotoxin above the threshold for PRs in humans.

Conclusions:

Reassessment of the acceptable amounts of endotoxin in gentamicin and other parenteral products should be considered when dosing intervals used in clinical practice change.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 21 , Issue 12 , December 2000 , pp. 771 - 774
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Nicolau, DP, Freeman, CD, Belliveau, PP, Nightingale, CH, Ross, JW, Quintiliani, R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995:39:650–655.CrossRefGoogle Scholar
2.Deamer, RL, Dial, LK. The evolution of aminoglycoside therapy: a single daily dose. Am Fam Physician 1996;53:1782–1786.Google ScholarPubMed
3.Centers for Disease Control and Prevention. Endotoxin-like reactions associated with intravenous gentamicin—California, 1998. MMWR 1998;47:877–880.Google Scholar
4.Arduino, MJ, Bland, LAMcAllister, SK, Aguero, SM, Villarino, ME, McNeil, MM, et al. Microbial growth and endotoxin production in the intravenous anesthetic propofol. Infect Control Hosp Epidemiol 1991;12:535–539.CrossRefGoogle ScholarPubMed
5.Beck-Sague, CM, Jarvis, WR, Bland, LAArduino, MJ, Aguero, SM, Verosic, G. Outbreak of gram-negative bacteremia and pyrogenic reactions in a hemodialysis center. Am J Nephrol 1990;10:397–403.CrossRefGoogle Scholar
6.Pegues, DAOettinger, CW, Bland, LAOliver, JC, Arduino, MJ, Aguero, SM, et al. A prospective study of pyrogenic reactions in hemodialysis patients using bicarbonate dialysis fluids filtered to remove bacteria and endotoxin. Am Soc Nephrol 1992;3:1002–1007.CrossRefGoogle ScholarPubMed
7.Burrell, R. Human responses to bacterial endotoxin. Circ Shock 1994;43:137–153.Google ScholarPubMed
8.Suffredini, AF, Fromm, RE, Parker, MM, Brenner, M, Kovacs, JA, Wesley, RAet al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989;321:280–287.CrossRefGoogle Scholar
9.Elin, RJ, Wolff, SM, McAdam, KP, Chedid, L, Audibert, F, Bernard, C, et al. Properties of reference Escherichia coli endotoxin and its phthalylated derivative in humans. J Infect Dis 1981;144:329–336.CrossRefGoogle ScholarPubMed
10.Hochstein, HD, Fitzgerald, EAMcMahon, FG, Vargas, R. Properties of US standard endotoxin (EC-5) in human male volunteers. J Endotoxin Res 1994;1:52–56.CrossRefGoogle Scholar
11.Novitsky, TJ, Roslansky, PF, Siber, GR, Warren, HS. Turbidimetric method for quantifying serum inhibition of the Limulus amoebocyte lysate. Clin Microbiol 1985;20:211–216.CrossRefGoogle Scholar
12.Krieger, JADuncan, L. Gentamicin contaminated with endotoxin. N Engl J Med 1999;340:11–22.CrossRefGoogle ScholarPubMed